Webster Cabergoline Trial
Cabergoline versus Bromocriptine in Hyperprolactinaemic Amenorrhoea
Patient / Population Intervention / Exposure Comparison Outcome
In 459 women with hyperprolactinaemic amenorrhoea, cabergoline 0.5–1.0 mg twice weekly achieved stable normoprolactinaemia, ovulation and pregnancy more often than bromocriptine.
N
459
Design
Double-blind RCT
Endpoint
Stable normoprolactinaemia
Relevance
3
ResultNormoprolactinaemia 83 % vs 59 % (p<0.001); ovulation/pregnancy 72 % vs 52 %; better tolerability.
Webster J, et al. N Engl J Med. 1994;331(14):904-909. 10.1056/NEJM199410063311403
Discussion & critique
Established cabergoline as first-line therapy for prolactinoma — a position unchanged for three decades.